PHILADELPHIA, Nov. 27, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (NasdaqGM:EURX - News) announced today the completion of a gastrointestinal (GI) bioavailability study on Zentase(tm) (EUR-1008), the Company’s lead product candidate for the treatment of exocrine pancreatic insufficiency (EPI). The study was conducted in chronic pancreatitis patients in the U.S.
